Therapeutic Effect and Side Effects of Danazol in Endometriosis

article OA: closed CC0 ⤵ 2 in-corpus citations
View on OpenAlex View on PubMed View at publisher
AI-generated summary by claude@2026-06, 2026-06-07

Danazol treatment for endometriosis resulted in high symptomatic improvement but limited physical regression, with a 44% pregnancy rate and 28% recurrence, and noted hepatocellular damage at higher doses.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

Danazol was administered to patients with endometriosis and infertility in a study designed to assess its therapeutic efficacy and side effects. Forty-six patients with endometriosis were treated with 300 mg or 400 mg/day of danazol for a mean duration of 22 weeks. Although the symptomatic improvement rate was greater than 90%, the improvement in cul-de-sac nodularity was 47% and endometriomas did not regress during danazol therapy. The pregnancy rate and recurrence rate following this drug regimen were 44% and 28%, respectively. These rates were similar to those obtained in a comparable group of patients treated with a pseudopregnancy regimen. Mild hepatocellular damage was observed in 43% of patients taking 400 mg/day of danazol, necessitating discontinuation of medication in some instances. On reducing the dosage to 300 mg/day, however, the incidence of hepatocellular damage was lowered to almost the same level as with treatment with pseudo-pregnancy therapy. After completion of danazol therapy ovulation returned quickly in all instances, hepatocellular damage disappeared and serum levels of GOT and GPT were rapidly restored to normal.

My notes (saved in your browser only)

Condition tags

mesh:D004715endometriosisinfertility

MeSH descriptors

Danazol Endometriosis Pregnadienes Adult Chemical and Drug Induced Liver Injury Danazol Danazol Endometriosis Female Follow-Up Studies Humans Infertility, Female Infertility, Female Pregnadienes Pregnancy Recurrence

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (10)

Cited by (2)

Source provenance

europepmc
last seen: 2026-06-04T01:30:01.192114+00:00
openalex
last seen: 2026-06-04T00:00:01.174412+00:00
pubmed
last seen: 2026-05-13T22:10:00.881616+00:00
License: CC0 · commercial use OK